Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials

Purpose: Sorafenib is the only approved drug in first-line treatment for hepatocellular carcinoma. Recently, the Phase III REFLECT trial proved lenvatinib not inferior to sorafenib, potentially establishing a new standard of care in this setting. The study showed that both have similar overall survi...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: Casadei Gardini, Andrea, Puzzoni, Marco, Montagnani, Francesco, Marisi, Giorgia, Tamburini, Emiliano, Cucchetti, Alessandro, Solaini, Leonardo, Foschi, Francesco Giuseppe, Conti, Fabio, Ercolani, Giorgio, Cascinu, Stefano, Scartozzi, Mario
Format: Artigo
Language:Inglês
Published: Dove 2019
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6499482/
https://ncbi.nlm.nih.gov/pubmed/31118665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S192572
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items